A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Makoto UenoChigusa MorizaneMasayuki FurukawaDaisuke SakaiYoshito KomatsuYousuke NakaiMasahiro TsudaMasato OzakaNobumasa MizunoManabu MutoAkira FukutomiMasafumi IkedaAkihito TsujiAkio KatanumaToshikazu MoriwakiTakeshi KajiwaraHiroshi IshiiYuji NegoroSatoshi ShimizuNoriko NemotoShingo KobayashiKeigo MakinoJunji FurusePublished in: Cancer medicine (2021)
Resminostat plus S-1 therapy improved neither PFS nor OS for patients with pre-treated BTCs. Addition of resminostat to S-1 was associated with higher incidence of TrAEs, but these were manageable (JapicCTI-183883).